Chi-Med trials with AstraZeneca show preliminary anti-tumour activity 1 234 567

Chi-Med trials with AstraZeneca show preliminary anti-tumour activity

livecharts.co.uk

Hutchison China MediTech - commonly known as Chi-Med - announced on Tuesday that both it and AstraZeneca presented preliminary safety and clinical activity data of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib/II proof-of-concept trials conducted in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET-amplification, who had progressed following first-line treatment with an EGFR inhibitor.

Full news

Share:

More:

1 234 567

1 234 567

1 234 567

1 234 567

1 234 567

1 234 567